131 related articles for article (PubMed ID: 38896382)
1. Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study.
Haselgruber S; Fernández-Crehuet-Serrano P; Fernández-Ballesteros MD; Padial-Gómez A; Hernández-Rodríguez JC; Ortiz-Álvarez J; Navarro-Guillamón P; Membrive-Jiménez C; Cuenca-Barrales C; Molina-Leyva A
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38896382
[TBL] [Abstract][Full Text] [Related]
2. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC; Passeron T; Pariser D; Wozniak MB; Li X; Uhlmann L; Lobach I; Martinez AL; Ravichandran S; Alarcon I; Offidani A; Alam MS; Mendes-Bastos P
Br J Dermatol; 2024 May; 190(6):836-845. PubMed ID: 38470171
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
4. Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study.
Fernandez-Crehuet P; Haselgruber S; Padial-Gomez A; Vasquez-Chinchay F; Fernandez-Ballesteros MD; López-Riquelme I; Jimenez-Gallo D; Segura-Palacios JM; Contreras-Steyls M; Osorio-Gómez GF; Hernández-Rodríguez JC; Sanchez-Diaz M; Cuenca-Barrales C; Arias-Santiago S; Molina-Leyva A
Dermatol Ther (Heidelb); 2023 Apr; 13(4):1029-1038. PubMed ID: 36892752
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study.
Martora F; Marasca C; Cacciapuoti S; Fariello F; Potestio L; Battista T; Scalvenzi M; Megna M
Clin Cosmet Investig Dermatol; 2024; 17():159-166. PubMed ID: 38283798
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study.
Gulliver W; Alavi A; Wiseman MC; Gooderham MJ; Rao J; Alam MS; Papp KA; Desjardins O; Jean C
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2431-2439. PubMed ID: 34378812
[TBL] [Abstract][Full Text] [Related]
7. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):755-762. PubMed ID: 37331620
[TBL] [Abstract][Full Text] [Related]
8. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):T755-T762. PubMed ID: 37479135
[TBL] [Abstract][Full Text] [Related]
9. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
Esme P; Akoglu G; Dalkıran CD; Caliskan E
Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
[TBL] [Abstract][Full Text] [Related]
10. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis.
Tsai YC; Hung CY; Tsai TF
Pharmaceutics; 2023 Apr; 15(5):. PubMed ID: 37242593
[No Abstract] [Full Text] [Related]
12. Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.
Marzano AV; Genovese G; Casazza G; Moltrasio C; Dapavo P; Micali G; Sirna R; Gisondi P; Patrizi A; Dini V; Bianchini D; Bianchi L; Fania L; Prignano F; Offidani A; Atzori L; Bettoli V; Cannavò SP; Venturini M; Bongiorno MR; Costanzo A; Fabbrocini G; Peris K
Br J Dermatol; 2021 Jan; 184(1):133-140. PubMed ID: 32119111
[TBL] [Abstract][Full Text] [Related]
13. Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study.
Dudink K; Bouwman K; Chen Y; DePrimo SE; Munoz-Elias EJ; Aarts P; Schappin R; Florencia EF; van Heeswijk B; Prens LM; van der Zee HH; Prens EP; van Straalen KR; Horváth B
Br J Dermatol; 2023 Apr; 188(5):601-609. PubMed ID: 36811949
[TBL] [Abstract][Full Text] [Related]
14. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial.
Ben Abdallah H; Bregnhøj A; Emmanuel T; Ghatnekar G; Johansen C; Iversen L
JAMA Dermatol; 2024 Jan; 160(1):63-70. PubMed ID: 38055242
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa.
Tzellos T; van Straalen KR; Kyrgidis A; Alavi A; Goldfarb N; Gulliver W; Jemec GBE; Lowes MA; Marzano AV; Prens EP; Sayed CJ; van der Zee HH; Zouboulis CC
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):395-401. PubMed ID: 36184889
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB; Jemec GBE; Alavi A; Reguiai Z; Gottlieb AB; Bechara FG; Paul C; Giamarellos Bourboulis EJ; Villani AP; Schwinn A; Ruëff F; Pillay Ramaya L; Reich A; Lobo I; Sinclair R; Passeron T; Martorell A; Mendes-Bastos P; Kokolakis G; Becherel PA; Wozniak MB; Martinez AL; Wei X; Uhlmann L; Passera A; Keefe D; Martin R; Field C; Chen L; Vandemeulebroecke M; Ravichandran S; Muscianisi E
Lancet; 2023 Mar; 401(10378):747-761. PubMed ID: 36746171
[TBL] [Abstract][Full Text] [Related]
19. Brodalumab for moderate-severe hidradenitis suppurativa: An open-label multicentric cohort study in real clinical practice.
Osorio-Gómez GF; Ortiz-Álvarez J; Diaz-Ceca D; Guijarro-Sánchez C; Conejo-Mir Sánchez J; Fernández Crehuet P
Australas J Dermatol; 2024 May; 65(3):254-259. PubMed ID: 38597096
[TBL] [Abstract][Full Text] [Related]
20. Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY Study.
Hafner A; Ghislain PD; Kovács R; Batchelor R; Katoulis AC; Kirby B; Banayan H; Schonbrun M
J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):2277-2284. PubMed ID: 34320249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]